Connect
MJA
MJA

Emergence of hetero-vancomycin-intermediate Staphylococcus aureus (hVISA) in Sydney

Iain B Gosbell, David H Mitchell, Helen Ziochos and Peter B Ward
Med J Aust 2003; 178 (7): . || doi: 10.5694/j.1326-5377.2003.tb05233.x
Published online: 7 April 2003

To the Editor: Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (vancomycin-intermediate S. aureus, or VISA) was initially described in Japan,1 then the United States,2 and subsequently other regions of the world. Recently, Ward and colleagues reported the initial Australian isolate — a heteroresistant VISA (hVISA) strain — in Melbourne, Victoria.3 We report the first isolation of hVISA in Sydney, New South Wales.




Correspondence: 

  • 1. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
  • 2. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327-332.
  • 3. Ward PB, Johnson PD, Grabsch EA, et al. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 2001; 175: 480-483.
  • 4. Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 2439-2444.
  • 5. Chambers HF. Clinical role of linezolid and quinupristin-dalfopristin in treatment of staphylococcal infections. Abstracts of the 10th International Symposium on Staphylococci and Staphylococcal Infections; 2002 16–19 Oct; Tsukuba, Japan, 2002. ISSSI-351-Abstract-03.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.